Luis Paz-Ares and Federico Cappuzzo share their insights on optimal timing for IO treatment in resectable NSCLC and reflect on key data presented at WCLC and ESMO 2024.

Clemens Wendtner, Talha Munir, and Alessandra Tedeschi look back on the year so far in CLL, reviewing developments from clinical trials as well as real-world and comparative studies before considering how data drive individual treatment decisions.

Stephan Stilgenbauer, Meletios Dimopoulos, and Stefano Luminari look back on ASH, highlighting developments with BTK inhibitor-based therapies in CLL and immunotherapies in FL.

Christian Buske, Wojciech Jurczak and Rebecca Auer explore the current treatment landscape for R/R FL and consider how new targeted and cellular therapies may transform patient outcomes.

Carol Moreno and Pier Luigi Zinzani share their highlights from two of the biggest annual events in hematology, focusing on developments that will shape the future of clinical practice in CLL and indolent lymphomas.

Se-Hoon Lee and Tejas Patil explore how molecular testing guides treatment decisions with immunotherapy in locally advanced NSCLC by reviewing their own clinical case studies and the supporting clinical trial data. 

Alessandra Tedeschi, Lucrecia Yáñez and Thorsten Zenz use interactive patient case studies to illustrate the role of prior treatment experience, genetic/cytogenetic changes, comorbidities, and patient preference in guiding treatment choices in R/R CLL.

Sandip Patel and Salma Jabbour discuss the importance of achieving pCR and the role of cfDNA in monitoring disease.

Luis Paz-Ares and Carlos Gil Ferreira review clinical approaches to treating unresectable and resectable NSCLC and highlight emerging data on the efficacy of chemo-IO induction therapy in locally advanced disease. 

Christian Buske, Paolo Ghia and Shirley D’Sa reflect on the data presented at ASH 2022 that are most relevant for clinical practice, highlighting developments in CAR-T, bispecific antibody, and BTK inhibitor therapies, and more.

Francesc Bosch, Stephan Stilgenbauer and Alessandra Tedeschi discuss the first-line treatment of patients with CLL, including the role of first-line chemotherapy and selecting continuous vs time-limited targeted therapy.

Steven Kao, Christopher Cao and Caian Zhou tackle unanswered questions surrounding the treatment of early-stage NSCLC, including whether neoadjuvant or adjuvant immunotherapy could be the future of treatment. 

Marina Garassino and Riyaz Shah focus on recent updates to screening and staging in NSCLC, including global differences in screening, the clinical impact socioeconomic factors have on initial staging, and the future of NSCLC diagnostics.

Christian Buske, Véronique Leblond, Wojciech Jurczak and Pier Luigi Zinzani cover the highlights in lymphoma management that were announced during ASCO and EHA 2022.

Paolo Ghia, Davide Rossi and Anna Schuh discuss diagnosis and prognosis in CLL, including a case study on the differential diagnosis of accelerated CLL and Richter’s syndrome and a debate on the clinical relevance of IGHV and TP53 as biomarkers.

Christian Buske, Paolo Ghia, Wojciech Jurczak and Véronique Leblond review the most exciting announcements from ASH 2021, covering key developments in a range of lymphomas and leukemias including MCL, DLBCL, and CLL.

Wojciech Jurczak, Federico Pea, Paolo Ghia and Alessandra Tedeschi review the role of BTK inhibition in the treatment of R/R B-cell malignancies, with a special focus on next-generation BTKis.

Christian Buske, Wojciech Jurczak and Meletios Dimopoulos cover the key challenges in managing B-cell malignancies during the COVID-19 pandemic, including new evidence-based insights and recommendations for treating aggressive and indolent lymphomas and managing COVID-19 vaccinations.

Alessandra Tedeschi, Roger Owen, Michael Lunn, Véronique Leblond and Joe-Elie Salem review multidisciplinary management of Waldenström’s macroglobulinemia, including provision of specialist care beyond hematology.

Christian Buske, Ramón García-Sanz, Véronique Leblond and Alessandra Tedeschi focus on treatment for patients with relapsed and refractory Waldenström’s macroglobulinemia, and look to the future of Waldenström’s macroglobulinemia treatment.

Véronique Leblond, Meletios Dimopoulos, Ramón García-Sanz and Wojciech Jurczak outline the topic of treatment initiation for Waldenström’s macroglobulinemia, exploring treatment options, monitoring, and unmet needs.

Christian Buske, Alessandra Tedeschi and Roger Owen chart the diagnostic journey in Waldenström’s macroglobulinemia, covering topics such as diagnostic criteria, techniques for testing, differential diagnoses, staging and the impact of specific disease-associated mutations.